May 07, 2009
Proposals sought from academic institutions and seed-to-early stage companies developing novel therapeutic approaches to prevent, treat or reverse nervous system damage in multiple sclerosis
Fast Forward, LLC, a wholly-owned subsidiary of the National MS Society, and EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced a commitment of $3 million in 2009 to support innovative early-stage projects directed towards the development of therapies to prevent treat, or reverse nervous system damage in MS. This is the first "Request for Proposals" (RFP) issued under the auspices of a multi-year collaboration between Fast Forward and EMD Serono to accelerate innovation and commercial development of MS therapies. Merck KGaA, the parent corporation of EMD Serono, Inc., will provide up to $19 million in total funding for the collaboration.
To read complete article please click this link that will re-direct you to the National MS Society website's article.
If not yet registered to receive the "Stu's Views and MS Related News", weekly MS related e-newsletter, then please Click Here to register.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You